Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Registry of Toxic Effects of Chemical Substances (RTECS)

Glutaraldehyde

RTECS #

MA2450000

CAS #

111-30-8

Updated

October 2017

Molecular Weight

100.13

Molecular Formula

C5H8O2

Synonyms

1,3-Diformylpropane
1,5-Pentanedial
1,5-Pentanedione
Aldehyd glutarowy (Polish)
Cidex
Glutaral
Glutaraldehyd (Czech)
Glutaraldehyde (ACGIH)
Glutardialdehyde
Glutaric dialdehyde
NCI-C55425
Potentiated acid glutaraldehyde
Sonacide

Skin and Eye Irritation and References

Route/OrganismDoseEffectReference
eye /rabbit 1 mg severeUCDS** 1/30/1970
eye /rabbit 250 µg/24H severe85JCAE -,272,1986
eye /woman 200 ppbTOXID9 72,292,2003
skin /human 1%/2DCODEDG 61,163,2009
skin /human 6 mg/3D- intermittent severe85DKA8 -,127,1977
skin /mouse 2.5%/3DTXCYAC 279,115,2011
skin /rabbit 13 mg open irritation test mildUCDS** 1/30/1970
skin /rabbit 2 mg/24H severe85JCAE -,272,1986

Mutation Data and Reference

System TestRoute/Organism/TissueDoseReference
Cytogenetic Analysisovary/hamster160 µg/LENMUDM 7,1,1985
DNA Damagelymphocyte/human10 µmol/LEMMUEG 17(Suppl 19),71,1991
DNA Damageleukocyte/human5 µmol/LMUREAV 468,93,2000
DNA Damagefibroblast/hamster20 µmol/L/1HMUREAV 649,146,2008
DNA Damageleukocyte/chicken8 pphCELLB5 5,45,1975
DNA Damagelymphocyte/mammal (species unspecified)2500 µmol/LMUREAV 283,131,1992
DNA Damagefibroblast/hamster2500 ppmSFCRAO 23,346,1970
DNA repair/Bacillus subtilis1 mg/LMUREAV 193,21,1988
micronucleus testfibroblast/hamster10 µmol/L/1HMUREAV 649,146,2008
mutation in mammalian somatic cellslymphocyte/mouse8 mg/LEMMUEG 11,91,1988
mutation in microorganisms/Salmonella typhimurium500 nmol/L (+enzymatic activation step)MUREAV 148,25,1985
mutation in microorganisms/Salmonella typhimurium150 µg/plate (-enzymatic activation step)ENMUDM 5(Suppl 1),3,1983
mutation in microorganisms/Escherichia coli62500 ng/plate (-enzymatic activation step)MUREAV 412,17,1998
mutation in microorganisms/Salmonella typhimurium6.25 µg/plate/48H (-enzymatic activation step)MUREAV 747,36,2012
mutation in microorganisms/Salmonella typhimurium6.25 mg/L/49H (-enzymatic activation step)MUREAV 747,36,2012
mutation in microorganisms/Salmonella typhimurium3.125 mg/L/49H (+enzymatic activation step)MUREAV 747,36,2012
mutation in microorganisms/Salmonella typhimurium6.25 µg/plate/48H (+enzymatic activation step)MUREAV 747,36,2012
mutation in microorganisms/Escherichia coli12.5 µg/plate/48H (-enzymatic activation step)MUREAV 747,36,2012
mutation in microorganisms/Escherichia coli12.5 mg/L/49H (-enzymatic activation step)MUREAV 747,36,2012
mutation in microorganisms/Escherichia coli25 µg/plate/48H (+enzymatic activation step)MUREAV 747,36,2012
mutation in microorganisms/Escherichia coli12.5 mg/L/49H (+enzymatic activation step)MUREAV 747,36,2012
mutation in microorganisms/Salmonella typhimurium0.025 mg/plate/3D (-enzymatic activation step)MUREAV 521,19,2002
mutation in microorganisms/Salmonella typhimurium25 µg/plate/72H (-enzymatic activation step)MUTAEX 15,495,2000
other mutation test systemsother cell types/non-mammalian species50 mmol/LECREAL 95,233,1975
sister chromatid exchangeovary/hamster110 µg/LENMUDM 7,1,1985
sister chromatid exchangefibroblast/hamster10 µmol/L/1HMUREAV 649,146,2008

Reproductive Effects Data and References

Route/OrganismDoseEffectReference
oral/rat 875 mg/kg (35D male)Reproductive: Paternal effects: Testes, epididymis, sperm duct

Reproductive: Paternal effects: Prostate, seminal vesicle, Cowper's gland, accessory glands
OYYAA2 12,11,1976
oral/rat 4370 mg/kg (35D prior to copulation)Reproductive: Maternal effects: Uterus, cervix, vaginaOYYAA2 12,11,1976
oral/rat 1 gm/kg (6-15D pregnant)Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)TOLED5 63,147,1992
oral/mouse 50 gm/kg (6-15D pregnant)Reproductive: Specific developmental abnormalities: Central nervous system

Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue)

Reproductive: Specific developmental abnormalities: Musculoskeletal system
TJADAB 22,51,1980
oral/mouse 8 gm/kg (6-15D pregnant)Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)TJADAB 22,51,1980
oral/rabbit 585 mg/kg (7-19D pregnant)Reproductive: Other effects on female

Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants)

Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)
NTIS** OTS0526410
oral/rat 5.3 gm/kg (84D male/70D pre-4W after birth)Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain)

Reproductive: Effects on newborn: Other postnatal measures or effects

Reproductive: Effects on newborn: Delayed effects
JTEHD6 61,107,2000
oral/rat 167.4 mg/kg (multigenerations)Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain)

Reproductive: Effects on newborn: Delayed effects
JTEHD6 61,107,2000

Tumorigenic Data and References

Route/OrganismDoseEffectReference
oral/rat lowest published toxic dose: 2912 mg/kg/104W- continuousTumorigenic: Carcinogenic by RTECS criteria

Blood: Leukemia

Tumorigenic: Increased incidence of tumors in susceptible strains
TXCYAC 175,177,2002
oral/rat lowest published toxic dose: 2912 mg/kg/104W- intermittentTumorigenic: Carcinogenic by RTECS criteria

Blood: Leukemia

Tumorigenic: Increased incidence of tumors in susceptible strains
TXCYAC 175,177,2002

Acute Toxicity Data and References

Route/OrganismDoseEffectReference
In Vitro/Human, leukemia cells Inhibitor Concentration (5 percent kill): 506 mg/L/30MIn Vitro Toxicity Studies: Cell countingTIVIEQ 27,857,2013
In Vitro/Human, leukemia cells Inhibitor Concentration Low: 1.40 mg/L/30MIn Vitro Toxicity Studies: Other assaysTIVIEQ 27,857,2013
In Vitro/Human, leukemia cells Inhibitor Concentration (25 percent kill): 5.3 mg/L/24HIn Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc.TIVIEQ 26,1150,2012
In Vitro/Human, leukemia cells Inhibitor Concentration (50 percent kill): 2.78 mg/L/24HIn Vitro Toxicity Studies: Other assaysTIVIEQ 26,1150,2012
In Vitro/Human, lung Inhibitor Concentration (50 percent kill): 7.8 gm/L/3HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 27,174,2013
In Vitro/Human, lung Inhibitor Concentration (50 percent kill): 0.6 gm/L/24HIn Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.)TIVIEQ 27,174,2013
In Vitro/Human, lung Inhibitor Concentration (50 percent kill): 0.8 gm/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 27,174,2013
In Vitro/Human, lung Inhibitor Concentration (50 percent kill): 0.6 gm/L/24HIn Vitro Toxicity Studies: Other assaysTIVIEQ 27,174,2013
In Vitro/Human, lung tumor Inhibitor Concentration (50 percent kill): 1.5 gm/L/24HIn Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.)TIVIEQ 27,174,2013
In Vitro/Human, lung tumor Inhibitor Concentration (50 percent kill): 1.4 gm/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 27,174,2013
In Vitro/Human, monocyte Inhibitor Concentration Low: 17.8 mg/L/2HIn Vitro Toxicity Studies: Other assaysTIVIEQ 27,1233,2013
In Vitro/Human, monocyte Inhibitor Concentration (20 percent kill): 69 µmol/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TOLED5 199,51,2010
In Vitro/Human, monocyte Inhibitor Concentration (20 percent kill): 69 µmol/L/2HIn Vitro Toxicity Studies: Other assaysTOLED5 199,51,2010
In Vitro/Human, skin Inhibitor Concentration (50 percent kill): 242.6 µmol/L/48HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TXAPA9 245,281,2010
In Vitro/Human, skin Inhibitor Concentration (50 percent kill): 24.3 µmol/L/48HIn Vitro Toxicity Studies: Other assaysTXAPA9 245,281,2010
In Vitro/jrdInhibitor Concentration (50 percent kill): 4.45 mg/L/24HIn Vitro Toxicity Studies: Other assaysTIVIEQ 28,626,2014
In Vitro/Mouse, fibroblast Inhibitor Concentration (50 percent kill): 0.1 gm/L/24HIn Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.)TIVIEQ 27,174,2013
In Vitro/Mouse, fibroblast Inhibitor Concentration (50 percent kill): 0.1 gm/L/24HIn Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.TIVIEQ 27,174,2013
inhalation/mouse lowest published toxic concentration: 6 ppm/1.5HBehavioral: Somnolence (general depressed activity)

Lung, Thorax, or Respiration: Respiratory depression
TXCYAC 279,115,2011
inhalation/rabbit lowest published toxic concentration: 500 ppmEye: Conjunctiva irritation

Lung, Thorax, or Respiration: Cough
VCVGK* -,404,1984
inhalation/rat lethal concentration (50 percent kill): 480 mg/m3/4HEPASR* 8EHQ-1290-1008
inhalation/woman lowest published toxic concentration: 200 ppbOlfaction: Other olfaction effectsTOXID9 72,292,2003
intraperitoneal/mouse lethal dose (50 percent kill): 13900 µg/kgIYKEDH 10,232,1979
intraperitoneal/rat lethal dose (50 percent kill): 17900 µg/kgIYKEDH 10,232,1979
intravenous/mouse lethal dose (50 percent kill): 15400 µg/kgOYYAA2 19,503,1980
intravenous/rat lethal dose (50 percent kill): 9800 µg/kgEPASR* 8EHQ-1290-1008
oral/duck lethal dose (50 percent kill): 820 mg/kgBehavioral: Somnolence (general depressed activity)

Behavioral: Food intake (animal)
NTIS** OTS0526410-1
oral/guinea pig lethal dose (50 percent kill): 50 mg/kgBehavioral: Altered sleep time (including change in righting reflex)

Behavioral: Somnolence (general depressed activity)

Behavioral: Excitement
GISAAA 52(3),77,1987
oral/mouse lethal dose (50 percent kill): 231 mg/kgLung, Thorax, or Respiration: Other changes

Liver: Other changes

Kidney, Ureter, and Bladder: Other changes
VCVGK* -,404,1984
oral/mouse lethal dose (50 percent kill): 100 mg/kgOYYAA2 19,503,1980
oral/rat lethal dose (50 percent kill): 140 mg/kgLung, Thorax, or Respiration: Other changes

Liver: Other changes

Kidney, Ureter, and Bladder: Other changes
VCVGK* -,404,1984
oral/rat lethal dose (50 percent kill): 134 mg/kgOYYAA2 19,503,1980
skin/mouse lowest published toxic dose: 1.25 mg/kgEye: Change in extra- ocular musclesTXCYAC 279,115,2011
skin/mouse lethal dose (50 percent kill): >5840 mg/kgSkin: After systemic exposure: Dermatitis, otherOYYAA2 12,11,1976
skin/rabbit lethal dose (50 percent kill): 560 µL/kgUCDS** 11/4/1971
skin/rat lethal dose (50 percent kill): >2500 mg/kgSkin: After systemic exposure: Dermatitis, otherOYYAA2 12,11,1976
subcutaneous/mouse lethal dose (50 percent kill): >590 mg/kgNIIRDN -,395,1995
subcutaneous/rat lethal dose (50 percent kill): >750 mg/kgNIIRDN -,395,1995

Other Multiple Dose Data and References

Route/OrganismDoseEffectReference
inhalation/mouse lowest published toxic concentration: 16 ppm/6H/2W- intermittentOlfaction: Other olfaction effects

Lung, Thorax, or Respiration: Other changes

Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field
NTPTR* NIH-93-3348
inhalation/mouse lowest published toxic concentration: 1000 ppb/6H/13W- intermittentOlfaction: Other olfaction effects

Nutritional and Gross Metabolic: Weight loss or decreased weight gain

Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field
NTPTR* NIH-93-3348
inhalation/mouse lowest published toxic concentration: 250 ppb/6H/2Y- intermittentOlfaction: Other olfaction effects

Nutritional and Gross Metabolic: Weight loss or decreased weight gain
TOXID9 48,341,1999
inhalation/rat lowest published toxic concentration: 5 ppm/6H/2W- intermittentOlfaction: Other olfaction effects

Lung, Thorax, or Respiration: Other changes

Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field
NTPTR* NIH-93-3348
inhalation/rat lowest published toxic concentration: 1000 ppb/6H/13W- intermittentOlfaction: Other olfaction effects

Nutritional and Gross Metabolic: Weight loss or decreased weight gain
NTPTR* NIH-93-3348
inhalation/rat lowest published toxic concentration: 500 ppb/6H/2Y- intermittentOlfaction: Other olfaction effects

Nutritional and Gross Metabolic: Weight loss or decreased weight gain

Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field
TOXID9 48,341,1999
oral/rat lowest published toxic dose: 12376 mg/kg/2Y- continuousKidney, Ureter, and Bladder: Other changes in urine composition

Kidney, Ureter, and Bladder: Changes in bladder weight

Nutritional and Gross Metabolic: Weight loss or decreased weight gain
TOXID9 15,203,1995
oral/rat lowest published toxic dose: 54600 µg/kg/26W- intermittentLiver: Fatty liver degeneration

Nutritional and Gross Metabolic: Weight loss or decreased weight gain

Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: True cholinesterase
GISAAA 52(3),77,1987
oral/rat lowest published toxic dose: 11410 mg/kg/7D- intermittentNutritional and Gross Metabolic: Weight loss or decreased weight gainNTIS** OTS0535072
oral/rat lowest published toxic dose: 122.5 mg/kg/1W- continuousBehavioral: Fluid intakeJTEHD6 61,107,2000
oral/rat lowest published toxic dose: 967 mg/kg/2W- continuousBehavioral: Food intake (animal)JTEHD6 61,107,2000
oral/rat lowest published toxic dose: 688.8 mg/kg/1W- continuousBehavioral: Food intake (animal)JTEHD6 61,107,2000
oral/rat lowest published toxic dose: 117.5 mg/kg/235D- intermittentEndocrine: Changes in thymus weight

Blood: Normocytic anemia

Blood: Changes in other cell count (unspecified)
VCVGK* -,404,1994
oral/rat lowest published toxic dose: 1547 mg/kg/13W- intermittentKidney, Ureter, and Bladder: Urine volume decreased or anuria

Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Multiple enzyme effects
TXCYAC 175,177,2002
oral/rat lowest published toxic dose: 9282 mg/kg/78W- intermittentKidney, Ureter, and Bladder: Urine volume decreased or anuria

Kidney, Ureter, and Bladder: Changes in kidney weight

Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Multiple enzyme effects
TXCYAC 175,177,2002
skin/mouse lowest published toxic dose: 0.375 mg/kg/3D- intermittentBlood: Other changesTXCYAC 279,115,2011
skin/mouse lowest published toxic dose: 3.75 mg/kg/3D- intermittentBlood: Other changes

Skin: After topical application: Cutaneous sensitization (experimental)
TXCYAC 279,115,2011
subcutaneous/rat lowest published toxic dose: 175 mg/kg/35D- continuousLiver: Changes in liver weight

Endocrine: Changes in spleen weight

Blood: Normocytic anemia
OYYAA2 12,11,1976

Reviews

OrganizationStandardReference
American Conference of Governmental Industrial Hygienists (ACGIH)Threshold Limit Value-ceiling concentration 0.05 ppm (sen)DTLVS* TLV/BEI,2013
American Conference of Governmental Industrial Hygienists (ACGIH)Threshold Limit Value-Not classifiable as a human carcinogenDTLVS* TLV/BEI,2013
TOXICOLOGY REVIEWDPIRDU 1(7),2,1981
TOXICOLOGY REVIEWCRTXB2 22,143,1992
TOXICOLOGY REVIEWJACTDZ 15,98,1996
TOXICOLOGY REVIEWMUREAV 543,201,2003
TOXICOLOGY REVIEWEMMUEG 39,69,2002
TOXICOLOGY REVIEWMUREAV 589,136,2005
TOXICOLOGY REVIEWHPCQA4 38,527,2007
TOXICOLOGY REVIEWHUTOX* -,649,1996
TOXICOLOGY REVIEWFCTOD7 47,1287,2009
TOXICOLOGY REVIEWTOLED5 199,203,2010
TOXICOLOGY REVIEWFCTOD7 55,596,2013

Standards and Regulations

OrganizationStandardReference
Environmental Protection Agency (EPA) Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) 1988 PESTICIDE SUBJECT TO REGISTRATION OR RE-REGISTRATIONFEREAC 54,7740,1989
Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV;
Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLV
Occupational Exposure Limit-AUSTRALIAceiling concentration 0.1 ppm (0.41 mg/m3), JUL2008
Occupational Exposure Limit-AUSTRIAMAK-TMW 0.1 ppm (0.4 mg/m3);KZW 0.1 ppm (0.4 mg/m3), sen, 2007
Occupational Exposure Limit-BELGIUMshort term exposure limit 0.05 ppm (0.21 mg/m3), MAR2002
Occupational Exposure Limit-DENMARKceiling concentration 0.2 ppm (0.8 mg/m3), MAY2011
Occupational Exposure Limit-FINLANDceiling concentration 0.1 ppm (0.42 mg/m3), NOV2011
Occupational Exposure Limit-FRANCEVME 0.1 ppm (0.4 mg/m3), VLE 0.2 ppm (0.8 mg/m3), FEB2006
Occupational Exposure Limit-GERMANYMAK 0.05 ppm (0.21 mg/m3), 2011
Occupational Exposure Limit-ICELANDshort term exposure limit 0.2 ppm (0.8 mg/m3), sen, NOV2011
Occupational Exposure Limit-JAPANceiling concentration 0.03 ppm, a1 sen, s1 sen, MAY2012
Occupational Exposure Limit-KOREAceiling concentration 0.2 ppm (0.7 mg/m3), 2006
Occupational Exposure Limit-MEXICOpeak 0.2 ppm (0.7 mg/m3), 2004
Occupational Exposure Limit-NEW ZEALANDshort term exposure limit 0.05 ppm, sen, JAN2002
Occupational Exposure Limit-NORWAYtime-weighted average 0.2 ppm (0.8 mg/m3), JAN1999
Occupational Exposure Limit-PERUshort term exposure limit 0,05 ppm (0,2 mg/m3), JUL2005
Occupational Exposure Limit-RUSSIAshort term exposure limit 5 mg/m3, JUN2003
Occupational Exposure Limit-SWEDENceiling concentration 0.2 ppm (0.8 mg/m3), Sen, JUN2005
Occupational Exposure Limit-SWITZERLANDMAK-week 0.05 ppm (0.21 mg/m3), KZG-week 0.1 ppm (0.42 mg/m3), sen, JAN2011
Occupational Exposure Limit-THE NETHERLANDSMAC-C 0.25 mg/m3, 2003
Occupational Exposure Limit-UNITED KINGDOMtime-weighted average 0.05 ppm (0.2 mg/m3);short term exposure limit 0.05 ppm (0.2 mg/m3), sen, OCT2007

NIOSH Documentation and Surveillance

OrganizationStandardReference
National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO GLUTARALDEHYDE-airceiling concentration 0.2 ppmNIOSH* DHHS #92-100,1992
National Occupational Exposure Survey 1983Hazard Code 84349; Number of Industries 35; Total Number of Facilities 9475; Number of Occupations 63; Total Number of Employees Exposed 367330; Total Number of Female Employees Exposed 265564
National Occupational Hazard Survey 1974Hazard Code 84349; Number of Industries 11; Total Number of Facilities 2069; Number of Occupations 25; Total Number of Employees Exposed 12954

Status in Federal Agencies

OrganizationReference
EPA GENETOX PROGRAM 1988, Negative: CHO gene mutation
EPA TSCA Section 8(b) CHEMICAL INVENTORY
EPA TSCA Section 8(d) unpublished health/safety studies
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001
NCI Carcinogenesis Studies (inhal);no evidence:mouse,rat
NIOSH Analytical Method, 1994: Glutaraldehyde, 2532
NIOSH CURRENT INTELLIGENCE BULLETIN #55, September 1991
NTP Toxicity studies, RPT# TOX-25, October 2000
OSHA ANALYTICAL METHOD #ID-64
TOP